Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam Inc. is positioned to capitalize on a significant market opportunity, with the potential to expand its annual revenue to between $1.3 billion and $2.6 billion by targeting 2.6 million elevated-risk patients and catering to the growing demand for early remote cardiac diagnoses. The company's proprietary Vector Electrocardiography technology has demonstrated high sensitivity (92-100%) and improving specificity (54-58%) in clinical trials, which strengthens its prospects for FDA clearance and subsequent market adoption. Additionally, the global mobile ECG devices market is projected to grow from $4.1 billion in 2024 to $8.9 billion by 2032, supporting the increasing prevalence of cardiac diseases and the rising demand for innovative telehealth solutions.

Bears say

HeartBeam Inc faces significant challenges that could adversely affect its financial performance and stock outlook. The company's potential inability to obtain timely reimbursement for its products may result in limited market demand, leading to diminished revenue and operating results. Furthermore, the auditors' going-concern opinion raises substantial doubts about HeartBeam's long-term viability without new funding, compounding concerns about negative cash flows projected for 2025 and 2026, potential stock dilution, and the risk of operational delays or interruptions due to regulatory changes and compliance issues.

HeartBeam (BEAT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.